Table 3 A comparison of MRZR studies in multiple sclerosis patients

Present study

n = 203 (PPMS: n = 103, RRMS: n = 100)

49%

76%

Reiber et al. [15]

n = 177 (no data concerning subtype)

[67%]

89%

Felgenhauer et al. [5]

n = 100 (no data concerning subtype)

[72%]

94%

Rosche et al. [24]

n = 68 (RRMS: n = 61, CIS: n = 7)

58%

[n.a.]

Brettschneider et al. [12]

n = 49 (CIS patients who converted to MS within 2 years)

47%

[n.a.]

Brecht et al.^a [19]

n = 46 (RRMS: n = 26, SPMS: n = 12, PPMS: n = 8)

[24%]

46%

Jarius et al. [7]

n = 42 (RRMS: n = 29, SPMS: n = 4, CIS: n = 9)

88%

[n.a.]

Bednarova et al. [10]

n = 42 (no data concerning subtype)

[47%]

88%

Hottenrott et al. [9]

n = 33 (RRMS: n = 14, SPMS: n = 5, PPMS: n = 14)

70%

[82%]

Kulakowska et al.^b [22]

n = 27 (RRMS: n = 21, PPMS: n = 6)

[56%]

81%

Tumani et al. [23]

n = 26 (no data concerning subtype)

[n.a.]

73%

Robinson-Agramonte et al. [21]

n = 23 (incomplete data concerning subtype)

[48%]

100%